34
Participants
Start Date
April 30, 2007
Primary Completion Date
February 12, 2019
Study Completion Date
February 12, 2019
Sunitinib Malate
Given PO
University of Maryland/Greenebaum Cancer Center, Baltimore
Northern Indiana Cancer Research Consortium, South Bend
Fort Wayne Medical Oncology and Hematology Inc - Jefferson Boulevard, Fort Wayne
University of Michigan Comprehensive Cancer Center, Ann Arbor
Oncology Care Associates PLLC, Saint Joseph
Froedtert and the Medical College of Wisconsin, Milwaukee
Loyola University Medical Center, Maywood
Evanston Hospital CCOP, Evanston
Ingalls Memorial Hospital, Harvey
Joliet Oncology-Hematology Associates Limited, Joliet
University of Chicago Comprehensive Cancer Center, Chicago
Illinois CancerCare-Peoria, Peoria
Decatur Memorial Hospital, Decatur
Central Illinois Hematology Oncology Center, Springfield
Southern Illinois University School of Medicine, Springfield
Mercy Hospital Saint Louis, St Louis
USC / Norris Comprehensive Cancer Center, Los Angeles
Tower Cancer Research Foundation, Beverly Hills
City of Hope Comprehensive Cancer Center, Duarte
City of Hope South Pasadena, South Pasadena
University of California Davis Comprehensive Cancer Center, Sacramento
Cross Cancer Institute, Edmonton
BCCA-Vancouver Cancer Centre, Vancouver
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
Kingston Health Sciences Centre, Kingston
Ottawa Hospital and Cancer Center-General Campus, Ottawa
Odette Cancer Centre- Sunnybrook Health Sciences Centre, Toronto
University Health Network-Princess Margaret Hospital, Toronto
Jewish General Hospital, Montreal
National Cancer Institute (NCI)
NIH